Phase I-/II-study of hyperfractionated-accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.

Trial Profile

Phase I-/II-study of hyperfractionated-accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HART-CIS-CET
  • Most Recent Events

    • 11 Oct 2016 Results (5-years) assessing feasibility, efficacy and safety of combination therapy with cisplatin, cetuximab and hyperfractionated-accelerated radiotherapy (n=74) presented at the 41st European Society for Medical Oncology Congress.
    • 12 Jul 2011 Additional trial identifiers (EudraCT2005-000355-15, KKSH19) identified, trial status is recruiting, planned patient patient number is 74 as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-000355-15)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top